転移性婦人科がん患者の生活の質を改善するための単回または多回分割緩和放射線療法
婦人科悪性腫瘍における健康関連の生活の質を改善するための緩和的骨盤放射線療法のランダム化第 II 相試験
This phase II trial studies if a single session of palliative radiation therapy can help improve symptoms of gynecologic cancers that have spread to other places in the body (metastatic) and that affect quality of life as well or more so than multiple sessions (which is the standard of care). Palliative radiation therapy may help patients with metastatic gynecologic cancers live more comfortably. Researchers also want to learn how radiation affects the immune system and to compare the effects of giving one radiation treatment to giving multiple radiation treatments.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To determine whether single fraction palliative radiation therapy (SFRT) improves the proportion of patients with improved Health-Related Quality of Life (HR-QOL) over multi-fraction palliative radiotherapy (MFRT).
SECONDARY OBJECTIVES:
I. To determine whether single fraction palliative radiation therapy (SFRT) improves overall health related quality of life (HR-QOL) over multi fraction palliative radiation therapy (MFRT).
II. To determine whether SFRT improves individual domains of HR-QOL over MFRT.
III. To determine whether SFRT increases clinically meaningful HR-QOL improvement over MFRT.
IV. To determine whether SFRT provides non-inferior symptom burden improvement (SBI) to MFRT.
EXPLORATORY OBJECTIVES:
I. To describe T-cell repertoire of patients receiving SFRT and MFRT.
II. To describe vaginal microbiome of patients receiving SFRT and MFRT.
III. To describe gut microbiome of patients receiving SFRT and MFRT.
IV. To describe financial burden of patients undergoing palliative pelvic radiation with either SFRT or MFRT.
V. To describe financial burden of patients undergoing palliative pelvic radiation with SFRT and MFRT.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo standard of care radiation therapy in the form of 3-dimensional conformal radiation therapy (3D CRT), intensity-modulated radiation therapy (IMRT), or volume modulated arc therapy (VMAT) at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the Symptom Inventory Scale (SIS) may receive an additional fraction on day 21 at the physician's discretion.
ARM B: Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 1 year.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital University
-
-
Ohio
-
Columbus、Ohio、アメリカ、43215
- OhioHealth
-
-
Texas
-
Houston、Texas、アメリカ、77030
- M D Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically or cytologically documented gynecologic cancer with prior or current evidence of metastatic disease
- Measurable pelvic disease with any pain and/or bleeding
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 3
- Estimated life expectancy > 3 months at discretion of treating physician
- Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
- Patient able to provide properly obtained written informed consent
- Gynecologic Section Radiation Oncology Quality Assurance (QA) for eligibility for single fraction radiation treatment
Exclusion Criteria:
- Prior pelvic radiation therapy that would make treatment unsafe at the discretion of the treating physician
- Systemic therapy concurrently or within 21 days of first dose of radiation
- Concurrent participation in another interventional radiation therapy trial concurrently or within 30 days of study consent. Note: Patients who are participating in systemic clinical trials and non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation
- Known second malignancy that requires active treatment (at the discretion of the primary investigator)
- Documented psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Pregnant or breastfeeding at any point starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A (radiation therapy)
Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion. |
Ancillary studies
他の名前:
Ancillary studies Undergo IMRT
他の名前:
Undergo 3D CRT
他の名前:
Undergo VMAT
他の名前:
|
|
アクティブコンパレータ:Arm B (radiation therapy)
Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity. |
Ancillary studies
他の名前:
Ancillary studies Undergo IMRT
他の名前:
Undergo 3D CRT
他の名前:
Undergo VMAT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Absolute change in index value of EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) score
時間枠:Baseline up to 21 days post-radiation therapy
|
An index value will be calculated for each participant according to page 13 of the user guide. Scores will be summarized using descriptive statistics. Will use a 2-sample t-test to compare the change scores between the single fraction palliative radiation therapy (SFRT) and multi-fraction palliative radiation therapy (MFRT) groups. |
Baseline up to 21 days post-radiation therapy
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Absolute change in mobility
時間枠:Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension. |
Baseline up to 21 days post-radiation therapy
|
|
Absolute change in self-care
時間枠:Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension. |
Baseline up to 21 days post-radiation therapy
|
|
Absolute change in activity
時間枠:Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension. |
Baseline up to 21 days post-radiation therapy
|
|
Absolute change in pain
時間枠:Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension. |
Baseline up to 21 days post-radiation therapy
|
|
Absolute change in anxiety
時間枠:Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self. Improvement within each dimension will be assessed by the absolute change of heath state. A decrease in the raw score by 1 or more points denotes improvement within the dimension. |
Baseline up to 21 days post-radiation therapy
|
|
>= 6 point increase in EuroQol-Visual Analogue Scale
時間枠:Baseline up to 21 days post-radiation therapy
|
Will summarize the number of patients with clinical meaningful health-related (HR)-quality of life (QOL) improvement using frequencies and proportions. The proportion of patients with clinically meaningful HR-QOL improvement will be compared between SFRT and MFRT using a chi-squared test. |
Baseline up to 21 days post-radiation therapy
|
|
Decrease in Symptom Inventory (SIS)
時間枠:At 21 days post-radiation therapy
|
Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test. Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions. The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test. |
At 21 days post-radiation therapy
|
|
Incidence of adverse events
時間枠:Within 21 days and up to 1 year
|
Assessed per Common Terminology Criteria for Adverse Events version 5.0. Radiation related toxicity event rates within 21 days and within one year for patients receiving SFRT and MFRT will be summarized using frequencies and proportions. Proportions between SFRT and MFRT will be compared using a chi-squared or Fisher's exact test. |
Within 21 days and up to 1 year
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
T-cell repertoire
時間枠:Up to 1 year
|
Will describe T-cell clonality, diversity, clonal overlap, productive and nonproductive frequencies using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies. |
Up to 1 year
|
|
Vaginal microbiome
時間枠:Up to 1 year
|
Will use alpha and beta diversity metrics for both 16S and whole-genome sequencing (WGS), including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies. |
Up to 1 year
|
|
Gut microbiome
時間枠:Up to 1 year
|
Will use alpha and beta diversity metrics for both 16S and WGS sequencing, including overall diversity, richness and evenness and species-specific microbial dynamics. Will be summarized using descriptive statistics. Informal comparisons may be completed to generate hypotheses for future studies. |
Up to 1 year
|
|
Financial burden
時間枠:Up to 21 days
|
Will be assessed using the Economic Strain and Resilience in Cancer Financial Toxicity Questionnaire. The scores for each question will be summarized using descriptive statistics. An overall average score will be calculated by calculating the mean score of the seven questions. At the end of the questionnaire, the patient is asked to rate their overall financial situation as much better, better, nearly the same, worse, or much worse. The frequency of each answer to the global question will be tabulated. |
Up to 21 days
|
協力者と研究者
捜査官
- 主任研究者:Lauren Colbert、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2020-0517
- 2020-0517 (その他の識別子:M D Anderson Cancer Center)
- NCI-2020-05684 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。